CD22 and non-Hodgkin lymphoma: Since most non-Hodgkin lymphomas (NHL) and B-ALL leukemic cells express surface CD22, a large number of preclinical and phase 1 studies evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of InO for CD22+ B-cell tumors [26].